Related Experiment Videos

Point/Counterpoint. NCI Clinical Alert policy. Shouldn't we see the white flag before we cry victory?

I C Henderson¹

¹Division of Clinical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115.

Journal of the National Cancer Institute

|January 17, 1990

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Breast cancer research and treatment·2008

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2005

Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Clinical cancer research : an official journal of the American Association for Cancer Research·2001

HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000

Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services.

Cancer·2000

See all related articles